Evidence map›Paper›PMID 35561704›Full record

ArticleThe lancet. HIV2022

Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19.

Silvia Bertagnolio, Soe Soe Thwin, Ronaldo Silva, Sairaman Nagarajan, Waasila Jassat, Robert Fowler, Rashan Haniffa, Ludovic Reveiz, Nathan Ford, Meg Doherty and 1 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in The lancet. HIV, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06683937 (Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024), which is not on this map. Cited by 117 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed, 2 pooled it
18.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06683937 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024

TypeobservationalSponsorAssistance Publique - Hôpitaux de ParisRan2025 to 2026Enrolled300ConditionsImmunocompromised Patients, SARS-CoV-2 DiseaseArmsCollection of data from the patient's medical file
3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 2 syntheses or guidelines pooled it, 190 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 6 countries.

Silvia BertagnolioDepartment of Global HIV, STI & Hepatitis Programmes, WHO, Geneva, Switzerland.
Soe Soe ThwinDepartment of Sexual and Reproductive Health and Research, WHO, Geneva, Switzerland.
Ronaldo SilvaDepartment of Sexual and Reproductive Health and Research, WHO, Geneva, Switzerland.
Sairaman NagarajanDepartments of Internal Medicine and Pediatrics, SUNY Downstate Medical Center, New York, USA.
Waasila JassatNational Institute for Communicable Diseases, Johannesburg, South Africa; Right to Care, Pretoria, South Africa.
Robert FowlerDepartment of Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada.
Rashan HaniffaMahidol Oxford Tropical Medicine Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK; National Intensive Care Surveillance-MORU, Colombo, Sri Lanka.
Ludovic ReveizDepartment of Evidence and Intelligence for Action in Health, Incident Management Systems, Pan American Health Organization, Washington DC, USA.
Nathan FordDepartment of Global HIV, STI & Hepatitis Programmes, WHO, Geneva, Switzerland.
Meg DohertyDepartment of Global HIV, STI & Hepatitis Programmes, WHO, Geneva, Switzerland.
Janet DiazDepartment of Country Readiness Strengthening, Health Emergencies Programme, WHO, Geneva, Switzerland.
World Health Organization · CHRight to Care · ZASunnybrook Health Science Centre · CASUNY Downstate Health Sciences University · USUniversity of Oxford · GBWorld Health Organization Regional Office for the Americas · US

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundWHO has established a Global Clinical Platform for the clinical characterisation of COVID-19 among hospitalised individuals. We assessed whether people living with HIV hospitalised with COVID-19 had increased odds of severe presentation and of in-hospital mortality compared with individuals who were HIV-negative and associated risk factors.

methodsBetween Jan 1, 2020, and July 1, 2021, anonymised individual-level data from 338 566 patients in 38 countries were reported to WHO. Using the Platform pooled dataset, we performed descriptive statistics and regression analyses to compare outcomes in the two populations and identify risk factors.

findingsOf 197 479 patients reporting HIV status, 16 955 (8·6%) were people living with HIV. 16 283 (96.0%) of the 16 955 people living with HIV were from Africa; 10 603 (62·9%) were female and 6271 (37·1%) were male; the mean age was 45·5 years (SD 13·7); 6339 (38·3%) were admitted to hospital with severe illness; and 3913 (24·3%) died in hospital. Of the 10 166 people living with HIV with known antiretroviral therapy (ART) status, 9302 (91·5%) were on ART. Compared with individuals without HIV, people living with HIV had 15% increased odds of severe presentation with COVID-19 (aOR 1·15, 95% CI 1·10-1·20) and were 38% more likely to die in hospital (aHR 1·38, 1·34-1·41). Among people living with HIV, male sex, age 45-75 years, and having chronic cardiac disease or hypertension increased the odds of severe COVID-19; male sex, age older than 18 years, having diabetes, hypertension, malignancy, tuberculosis, or chronic kidney disease increased the risk of in-hospital mortality. The use of ART or viral load suppression were associated with a reduced risk of poor outcomes; however, HIV infection remained a risk factor for severity and mortality regardless of ART and viral load suppression status.

interpretationIn this sample of hospitalised people contributing data to the WHO Global Clinical Platform for COVID-19, HIV was an independent risk factor for both severe COVID-19 at admission and in-hospital mortality. These findings have informed WHO immunisation policy that prioritises vaccination for people living with HIV. As the results mostly reflect the data contribution from Africa, this analysis will be updated as more data from other regions become available.

fundingNone. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.

Indexed as

COVID-19HIV InfectionsHypertensionAdolescentAgedFemaleHospitalsHumansMaleMiddle AgedRisk FactorsWorld Health Organization

Identifiers

PMID35561704
PMCPMC9090268
OpenAlexW4280530640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.